Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy

Midori Hasegawa, Fumiko Kondo, Koichiro Yamamoto, Kazutaka Murakami, Makoto Tomita, Kunihiro Nabeshima, Shigeru Nakai, Masao Kato, Atsushi Ohashi, Jiro Arai, Yoshiyuki Hiki, Junichi Ishii, Nobuhiko Emi, Satoshi Sugiyama, Yukio Yuzawa

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aggressive removal of circulating free light chains (FLC) by blood purification accompanied by chemotherapy is a promising approach for the treatment of acute renal failure due to myeloma cast nephropathy. Plasma exchange has been performed to remove serum FLC; in order to examine an alternative strategy we performed hemodiafiltration using protein-leaking dialyzers for the treatment of dialysis-dependent acute renal failure due to myeloma cast nephropathy. In the first case with κ-light chain cast nephropathy, the pre-treatment serum creatinine was 9.65 mg/dL, and the serum κ-FLC was 27 100 mg/L. Plasma exchange or hemodiafiltration was performed from Monday to Friday during the first several weeks. Chemotherapy was started with high-dose dexamethasone and then switched to bortezomib plus dexamethasone. The mean removal rates of κ-FLC were 45.8% (one plasma volume) and 66.9% (one-and-a-half plasma volumes) by plasma exchange. The removal rates of κ-FLC by hemodiafiltration (66.9%, FB210UHβ; 71.6%, PES210Dα; 75.2%, FXS220) were comparable to those by plasma exchange. In the second case with γ-light chain cast nephropathy, the pre-treatment serum creatinine was 4.14 mg/dL, and the serum γ-FLC was 4140 mg/L. The mean removal rates of γ-FLC were 60.2% (FXS140) and 64.2% (FB210UHβ) by hemodiafiltration. Both cases became dialysis-independent. The combination of an intense blood purification regimen and bortezomib plus dexamethasone therapy appears to be an efficient approach to renal recovery. Hemodiafiltration using protein-leaking dialyzers could become an alternative to plasma exchange as a method of removing FLC.

Original languageEnglish
Pages (from-to)451-456
Number of pages6
JournalTherapeutic Apheresis and Dialysis
Volume14
Issue number5
DOIs
Publication statusPublished - 01-10-2010

Fingerprint

Acute Kidney Injury
Dexamethasone
Hemodiafiltration
Light
Plasma Exchange
Therapeutics
Serum
Plasma Volume
Dialysis
Creatinine
Bortezomib
Drug Therapy
Proteins
Kidney

All Science Journal Classification (ASJC) codes

  • Hematology
  • Nephrology

Cite this

Hasegawa, Midori ; Kondo, Fumiko ; Yamamoto, Koichiro ; Murakami, Kazutaka ; Tomita, Makoto ; Nabeshima, Kunihiro ; Nakai, Shigeru ; Kato, Masao ; Ohashi, Atsushi ; Arai, Jiro ; Hiki, Yoshiyuki ; Ishii, Junichi ; Emi, Nobuhiko ; Sugiyama, Satoshi ; Yuzawa, Yukio. / Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy. In: Therapeutic Apheresis and Dialysis. 2010 ; Vol. 14, No. 5. pp. 451-456.
@article{d517b262293b4d2292de521532b311e4,
title = "Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy",
abstract = "Aggressive removal of circulating free light chains (FLC) by blood purification accompanied by chemotherapy is a promising approach for the treatment of acute renal failure due to myeloma cast nephropathy. Plasma exchange has been performed to remove serum FLC; in order to examine an alternative strategy we performed hemodiafiltration using protein-leaking dialyzers for the treatment of dialysis-dependent acute renal failure due to myeloma cast nephropathy. In the first case with κ-light chain cast nephropathy, the pre-treatment serum creatinine was 9.65 mg/dL, and the serum κ-FLC was 27 100 mg/L. Plasma exchange or hemodiafiltration was performed from Monday to Friday during the first several weeks. Chemotherapy was started with high-dose dexamethasone and then switched to bortezomib plus dexamethasone. The mean removal rates of κ-FLC were 45.8{\%} (one plasma volume) and 66.9{\%} (one-and-a-half plasma volumes) by plasma exchange. The removal rates of κ-FLC by hemodiafiltration (66.9{\%}, FB210UHβ; 71.6{\%}, PES210Dα; 75.2{\%}, FXS220) were comparable to those by plasma exchange. In the second case with γ-light chain cast nephropathy, the pre-treatment serum creatinine was 4.14 mg/dL, and the serum γ-FLC was 4140 mg/L. The mean removal rates of γ-FLC were 60.2{\%} (FXS140) and 64.2{\%} (FB210UHβ) by hemodiafiltration. Both cases became dialysis-independent. The combination of an intense blood purification regimen and bortezomib plus dexamethasone therapy appears to be an efficient approach to renal recovery. Hemodiafiltration using protein-leaking dialyzers could become an alternative to plasma exchange as a method of removing FLC.",
author = "Midori Hasegawa and Fumiko Kondo and Koichiro Yamamoto and Kazutaka Murakami and Makoto Tomita and Kunihiro Nabeshima and Shigeru Nakai and Masao Kato and Atsushi Ohashi and Jiro Arai and Yoshiyuki Hiki and Junichi Ishii and Nobuhiko Emi and Satoshi Sugiyama and Yukio Yuzawa",
year = "2010",
month = "10",
day = "1",
doi = "10.1111/j.1744-9987.2010.00863.x",
language = "English",
volume = "14",
pages = "451--456",
journal = "Therapeutic Apheresis and Dialysis",
issn = "1744-9979",
publisher = "Wiley-Blackwell",
number = "5",

}

Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy. / Hasegawa, Midori; Kondo, Fumiko; Yamamoto, Koichiro; Murakami, Kazutaka; Tomita, Makoto; Nabeshima, Kunihiro; Nakai, Shigeru; Kato, Masao; Ohashi, Atsushi; Arai, Jiro; Hiki, Yoshiyuki; Ishii, Junichi; Emi, Nobuhiko; Sugiyama, Satoshi; Yuzawa, Yukio.

In: Therapeutic Apheresis and Dialysis, Vol. 14, No. 5, 01.10.2010, p. 451-456.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy

AU - Hasegawa, Midori

AU - Kondo, Fumiko

AU - Yamamoto, Koichiro

AU - Murakami, Kazutaka

AU - Tomita, Makoto

AU - Nabeshima, Kunihiro

AU - Nakai, Shigeru

AU - Kato, Masao

AU - Ohashi, Atsushi

AU - Arai, Jiro

AU - Hiki, Yoshiyuki

AU - Ishii, Junichi

AU - Emi, Nobuhiko

AU - Sugiyama, Satoshi

AU - Yuzawa, Yukio

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Aggressive removal of circulating free light chains (FLC) by blood purification accompanied by chemotherapy is a promising approach for the treatment of acute renal failure due to myeloma cast nephropathy. Plasma exchange has been performed to remove serum FLC; in order to examine an alternative strategy we performed hemodiafiltration using protein-leaking dialyzers for the treatment of dialysis-dependent acute renal failure due to myeloma cast nephropathy. In the first case with κ-light chain cast nephropathy, the pre-treatment serum creatinine was 9.65 mg/dL, and the serum κ-FLC was 27 100 mg/L. Plasma exchange or hemodiafiltration was performed from Monday to Friday during the first several weeks. Chemotherapy was started with high-dose dexamethasone and then switched to bortezomib plus dexamethasone. The mean removal rates of κ-FLC were 45.8% (one plasma volume) and 66.9% (one-and-a-half plasma volumes) by plasma exchange. The removal rates of κ-FLC by hemodiafiltration (66.9%, FB210UHβ; 71.6%, PES210Dα; 75.2%, FXS220) were comparable to those by plasma exchange. In the second case with γ-light chain cast nephropathy, the pre-treatment serum creatinine was 4.14 mg/dL, and the serum γ-FLC was 4140 mg/L. The mean removal rates of γ-FLC were 60.2% (FXS140) and 64.2% (FB210UHβ) by hemodiafiltration. Both cases became dialysis-independent. The combination of an intense blood purification regimen and bortezomib plus dexamethasone therapy appears to be an efficient approach to renal recovery. Hemodiafiltration using protein-leaking dialyzers could become an alternative to plasma exchange as a method of removing FLC.

AB - Aggressive removal of circulating free light chains (FLC) by blood purification accompanied by chemotherapy is a promising approach for the treatment of acute renal failure due to myeloma cast nephropathy. Plasma exchange has been performed to remove serum FLC; in order to examine an alternative strategy we performed hemodiafiltration using protein-leaking dialyzers for the treatment of dialysis-dependent acute renal failure due to myeloma cast nephropathy. In the first case with κ-light chain cast nephropathy, the pre-treatment serum creatinine was 9.65 mg/dL, and the serum κ-FLC was 27 100 mg/L. Plasma exchange or hemodiafiltration was performed from Monday to Friday during the first several weeks. Chemotherapy was started with high-dose dexamethasone and then switched to bortezomib plus dexamethasone. The mean removal rates of κ-FLC were 45.8% (one plasma volume) and 66.9% (one-and-a-half plasma volumes) by plasma exchange. The removal rates of κ-FLC by hemodiafiltration (66.9%, FB210UHβ; 71.6%, PES210Dα; 75.2%, FXS220) were comparable to those by plasma exchange. In the second case with γ-light chain cast nephropathy, the pre-treatment serum creatinine was 4.14 mg/dL, and the serum γ-FLC was 4140 mg/L. The mean removal rates of γ-FLC were 60.2% (FXS140) and 64.2% (FB210UHβ) by hemodiafiltration. Both cases became dialysis-independent. The combination of an intense blood purification regimen and bortezomib plus dexamethasone therapy appears to be an efficient approach to renal recovery. Hemodiafiltration using protein-leaking dialyzers could become an alternative to plasma exchange as a method of removing FLC.

UR - http://www.scopus.com/inward/record.url?scp=77957333484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957333484&partnerID=8YFLogxK

U2 - 10.1111/j.1744-9987.2010.00863.x

DO - 10.1111/j.1744-9987.2010.00863.x

M3 - Article

VL - 14

SP - 451

EP - 456

JO - Therapeutic Apheresis and Dialysis

JF - Therapeutic Apheresis and Dialysis

SN - 1744-9979

IS - 5

ER -